上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注信达生物要玩把大的——挑战癌王。近日,信达生物在CDE药物临床试验登记与信息公示平台上登记了一项CLDN18.2 ADC药物IBI343对比安慰剂联合最佳支持治疗的至少接受过两次系统治疗CLDN18.2阳性局部晚期或转移性胰腺癌三期临床。这项三期的开启意义重大,这是全球首个开启胰腺癌三期临床的ADC,也是首个开启胰腺癌...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.